Investigational drug · Phase 3
Utomilumab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Malignancies, NSCLC, Ovarian Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
17
Any phase or sponsor naming "Utomilumab"
First trial start
2021
Sep 29, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Utomilumab", any sponsor or status.
- Phase 112
Conditions studied
As listed on its trial records.
- Advanced Malignancies
- NSCLC
- Ovarian Cancer
- Urothelial Cancer
- Solid Tumors
Approved drugs for the same conditions: Non-small cell lung cancer · Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Utomilumab" as an intervention, largest first.
- A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)Pivotal-lookingTerminated
PfizerPfizer (PFE)
NCT02554812 · 409 participants · Start Nov 9, 2015 · Primary completion Mar 23, 2023
Drug: Avelumab; Utomilumab and 3 more · For: Advanced Cancer
Sites: Encinitas, California; La Jolla, California; Los Angeles, California · 88 sites in all
PfizerPfizer (PFE)
NCT01307267 · 190 participants · Start Jun 21, 2011 · Primary completion Feb 20, 2019
Drug: PF-05082566; rituximab and 1 more · For: Lymphoma, Non-Hodgkin; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse and 4 more
Sites: Duarte, California; La Jolla, California; Los Angeles, California · 42 sites in all
PfizerPfizer (PFE)
NCT02315066 · 174 participants · Start Apr 23, 2015 · Primary completion Nov 12, 2020
Drug: PF-04518600; PF-04518600 and 2 more · For: Neoplasms
Sites: Los Angeles, California; Newport Beach, California; Santa Monica, California · 30 sites in all
- Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced MalignanciesActive, not recruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT03217747 · 173 participants · Start Aug 2, 2017 · Primary completion Sep 2, 2025
Drug: Avelumab; Ivuxolimab and 1 more · For: Advanced Malignant Solid Neoplasm; Castration-Resistant Prostate Carcinoma; Malignant Solid Neoplasm and 7 more
Sites: Houston, Texas
- Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast CancerPivotal-lookingActive, not recruiting
Laura Huppert, MD, BAAcademic, hospital or other
NCT03971409 · 145 participants · Start Jul 8, 2019 · Primary completion Jan 31, 2027
Drug: Anti-OX40 Antibody PF-04518600; Avelumab and 4 more · For: Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer and 6 more
Sites: Birmingham, Alabama; San Francisco, California; Washington D.C., District of Columbia · 12 sites in all
- The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast CancerPivotal-lookingActive, not recruiting
Adrienne G. WaksAcademic, hospital or other
NCT03414658 · 100 participants · Start Jun 21, 2018 · Primary completion May 1, 2023
Drug: Vinorelbine; Trastuzumab and 2 more · For: Breast Cancer
Sites: Birmingham, Alabama; San Francisco, California; Washington D.C., District of Columbia · 17 sites in all
- Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT05059522 · 77 participants · Start Sep 29, 2021 · Primary completion Dec 31, 2026
Drug: Avelumab; Lorlatanib and 6 more · For: Advanced Malignancies; NSCLC; Ovarian Cancer and 2 more
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 71 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT03290937 · 34 participants · Start Dec 27, 2017 · Primary completion Dec 30, 2025
Drug: Cetuximab; Irinotecan Hydrochloride and 1 more · For: Metastatic Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8 and 2 more
Sites: Houston, Texas
- Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)Pivotal-lookingTerminated
PfizerPfizer (PFE)
NCT02951156 · 29 participants · Start Dec 16, 2016 · Primary completion Dec 2, 2019
Drug: Avelumab; Utomilumab and 4 more · For: Diffuse Large B-Cell Lymphoma
Sites: Duarte, California; Louisville, Kentucky; New Orleans, Louisiana · 29 sites in all
- A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid TumorsTerminated
PfizerPfizer (PFE)
NCT02444793 · 24 participants · Start May 2015 · Primary completion Sep 2017
Drug: PF-05082566; KW-0761 · For: Advanced/Metastatic Solid Tumors
Sites: La Jolla, California; San Diego, California; Washington D.C., District of Columbia · 21 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Expanding the horizons of cancer therapy with next-generation 4-1BB agonists: a review of molecular and clinical strategies to maximize efficacy and ensure safety.
You G, Choi J, Yang C, et al. · MAbs 2026
- Tumor microenvironment changes after treatment with avelumab and immune-stimulating agent combinations in patients with advanced solid tumors.
Lermi NO, Gouda MA, Ahmed J, et al. · Res Sq 2026
- Development of a nanoparticle-based immunotherapy targeting CD137 for nasopharyngeal carcinoma treatment.
Lee KY, Sun H, Mei Y, et al. · Theranostics 2026
- A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies.
Ahmed J, Knisely A, Torrado C, et al. · Oncologist 2025
- M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation.
Xu C, Zhou X, Webb L, et al. · Cancer Immunol Res 2024
- Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
Knisely A, Ahmed J, Stephen B, et al. · Cancer 2024
Also in development for Advanced Malignancies
- LBL-007AlcestobartPhase 38 trials
BeOne Medicines (BeiGene) · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
- GimistotugBGB-A445Phase 34 trials
BeOne Medicines (BeiGene) · Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma
- PelabresibDAK539, CPI-0610Phase 34 trials
Novartis · Myelofibrosis, Primary Myelofibrosis, Primary Myelofibrosis (PMF)
- TQB2930Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · HER2-positive Advanced Breast Cancer, Colorectal Cancer, Metastatic Breast Cancer
- TQB3616Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
- BGB-15025Phase 33 trials
BeOne Medicines (BeiGene) · Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Advanced Malignancies
- SurzebiclimabBGB-A425Phase 33 trials
BeOne Medicines (BeiGene) · Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion
- CMP 001VidutolimodPhase 32 trials
Pfizer · Advanced Malignancies, NSCLC, Ovarian Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.